Coronavirus can set off a ‘cytokine storm.’ These drugs may calm it.

By Apoorva Mandavilli

Many coronavirus patients seem to get better at first, then rapidly decline and are overtaken by an overwhelming immune response that causes the body to turn on itself.

This “cytokine storm” was once an arcane phenomenon familiar mainly to rheumatologists who study when and how the immune system’s safeguards fail.

But it has become increasingly clear in the past few months that, at least in a subset of people who have the virus, calming the storm is the key to survival.

At least a dozen candidate drugs to treat the coronavirus rely on this premise. A few de- vices that purify the blood, as dialysis machines do, are also being tested. One promising drug made by Roche is in several clinical trials, in- cluding a late-stage trial in combination with the antiviral drug remdesivir. And a recent paper in the journal Science Immunology described preliminary data on a drug that stems the flood of cytokines at its source, and seems to lead to rapid recovery.

When immune cells first encounter a pathogen, they release molecules called cy- tokines to recruit even more cells to the fight. Once the danger recedes, the immune system usually turns itself off. But occasionally “it doesn’t shut up,” said Dr. Jose Scher, a rheuma- tologist at New York University Langone Health. “The immune system goes on and on and on and on.”

This unrelenting response can exhaust the immune system; shut down lungs, kidneys and liver; and prove fatal. It can do so even in young people and children who have no un- derlying conditions. In a milder form, this same mechanism is at play in autoimmune diseases like lupus and rheumatoid arthritis. Most of the drugs that doctors have tried for the coronavirus, including steroids and hydroxychloroquine, are treatments for those diseases, disrupting their supplies.

“Our medicines have been co-opted from us,” said Scher, adding that they are often being deployed with little insight into their proper use or pitfalls.

Early in the pandemic, doctors in China and Italy recognized the telltale signs of a body in cytokine shock — fever, a racing heart and plummeting blood pressure — and treated pa- tients with the drug tocilizumab. That drug is marketed by Roche as Actemra, which blocks a cytokine called interleukin-6.

Anecdotal evidence and preliminary tri- als soon confirmed their hunch. Since then, sev- eral studies have shown that high levels of IL-6 portend respiratory failure and death, and that Actemra lowers these risks.

Other drugs that quell IL-6 activity have shown promising results, as has Kineret, a drug that quiets a different cytokine called IL-1.

A more efficient solution than blocking any single cytokine would be to break the cycle of inflammation at its origin, experts said. For example, blood pressure drugs that mute the chemical signals that precede cytokines have shown some benefit in mouse studies and are being tested in people.

In the paper published in Science Im- munology, scientists identified that the cancer drug Calquence, made by AstraZeneca and also called acalabrutinib, can cut off the cytokine supply at its source.

Treating patients with drugs like tocili- zumab is “like cutting the branches off a tree,” said Dr. Louis Staudt, a scientist at the National Cancer Institute who was one of the lead inves- tigators of the study. “Acalabrutinib is going for the trunk of the tree.”

The team identified macrophages — scav- enger cells that chew up bacteria and viruses — as the key source of the cytokine surge in CO- VID-19, the disease caused by the coronavirus. “These patients get in trouble because their house is on fire in their lungs,” Staudt said. “This drug can put out this inflammatory fire by disabling macrophages.”

The involvement of macrophages might also explain why some people suddenly deterio- rate weeks into infection. Large number of the cells would become involved only after the virus had substantially damaged the lungs. “There’s a time delay there,” he said.

People who have diabetes, obesity and hypertension have a higher baseline of inflam- mation, so it’s also possible, he said, that this may explain why they are particularly vulnera- ble to becoming seriously ill. AstraZeneca plans to test Calquence in larger trials.

The insights gained from studying COV- ID-19, especially because of the large numbers of people affected, might allow researchers to understand inflammatory syndromes that have long remained mysterious, Staudt said.

The pandemic has also popularized an approach that is commonplace for treating some diseases, but has not been proved in clinical tri- als to work for coronavirus patients.

For example, the Food and Drug Admin- istration has authorized the use of a cartridge that continually filters excess cytokines from the blood, similar to the way a dialysis ma- chine removes toxins. The purified blood is then pumped back into the body.

The device, called CytoSorb, is about the size of a drinking glass and is filled with coarse polymers, each roughly the size of a grain of salt. Every grain, or bead, has millions of pores and channels that add up to a surface area of roughly seven football fields and filter out mol- ecules roughly the size of cytokines. One car- tridge can purify an entire body’s blood volume roughly 70 times in a 24-hour period.

Bigger objects like cells go around the eads and are unaffected, and smaller things like electrolytes go straight through, said Dr. Phillip Chan, the chief executive of CytoSor- bents Corp., which makes the device. CytoSorb may also remove some proteins that the body needs.

But “in a life-threatening illness when you have a cytokine storm,” Chan said, “it’s more or less a race to remove what will kill you ver- sus the temporary inconvenience of removing things that your body manufactures all the time anyway.”

In Europe, where CytoSorb has been com- mercially available since 2013, it has been used more liberally. But in the United States, the de vice had been allowed only for patients who had exhausted all other options. Even now, during the pandemic, its use is authorized only in coronavirus patients who are critically ill, with imminent or confirmed respiratory failure.

Dr. Stephan Ziegeler, who leads a special- ized pulmonary intensive care unit at a hospital in Ibbenbüren, Germany, has so far treated eight people with CytoSorb. (Since 2018, he has re- ceived speaking fees from CytoSorb’s manufac- turer, totaling 5,000 euros, or about $5,600.) Of these people, three have been discharged, three are being weaned off ventilation and two have died.

Patients with bacterial sepsis typically need a maximum of three cartridges — one per day at $1,200 — but coronavirus patients have such astronomical levels of cytokines, Ziegeler said, that some have needed dozens of cycles, with two fresh cartridges per day.

“It seems that COVID-19 has a prolonged cytokine storm — a prolonged, really effective inflammatory state compared to other sepsis states,” he said.

CytoSorb is not the only mechanical ap- proach being used; the FDA has also authorized the use of another device, called Oxiris, for coronavirus patients. And there are plans to try CytoSorb in combination with tocilizumab.

All of these approaches are worth pursu- ing, Scher said, but they all must be tested in rig- orous clinical trials with the right control groups: “That will be the only way to learn for sure.”

3 views0 comments